Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 16/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700227 | 0.94 | CA2 (0.43) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL1958639 | 0.83 | CA2 (0.41) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL1960063 | 0.81 | CA2 (0.44) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL1956646 | 0.81 | CA2 (0.46) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL1866518 | 0.80 | CA2 (0.43) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL1959371 | 0.80 | CA2 (0.45) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL1958846 | 0.79 | CA2 (0.42) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL28092192 | 0.79 | TDP1 (0.49) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL1958484 | 0.78 | CA2 (0.43) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL1956266 | 0.77 | VCAM1 (0.43) | VCAM1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376480-A2 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010065865-A2 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |